Location: 34-401 (Grier Room)
Speaker: Vishal Tandon, Draper
Abstract: Autologous cellular therapies based on T cells genetically-modified to express chimeric antigen receptor genes have been effective in treating hematological cancers, but the complexity and costs associated with current methods for manufacturing these therapies limit their widespread accessibility. Draper has developed a series of microfluidic tools to improve and automate the unit processes in the cell therapy manufacturing pipeline, helping to reduce costs and manufacturing time.
Bio: Vishal is a senior member of the technical staff at Draper who leads development of electrotransfection platforms for applications in cellular therapy manufacturing. Vishal received his Ph.D. in biomedical engineering from Cornell University, where he examined fundamental electrokinetic properties of hydrophobic, microfluidic substrates.